---
title: "[22] O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer"
featured_title: "Sugar Coating Drives Drug Resistance in Breast Cancer"
authors: ["Y Zhang*", "S Zhou*", "Yan Kai*", "Y Zhang", "C Peng", "Z Li", "MJ Mughal", "B Julie", "et al."]
date: "2024-07-01"
weight: 3
publication_types: ["article-journal"]
publication: "*Nature Communications* 15 (1), 5597"
featured: true
image:
  caption: 'MITF Modification'
  focal_point: ""
  preview_only: false
summary: "We identified O-GlcNAcylation as a critical regulator of MITF activity, driving resistance to CDK4/6 inhibitors in breast cancer."
---

CDK4/6 inhibitors (e.g., palbociclib) have revolutionized the treatment of hormone receptor-positive breast cancer. However, resistance inevitably emerges, leading to treatment failure. Understanding the mechanisms of this resistance is crucial for developing next-generation therapies.

In this study, we identified a novel mechanism of resistance involving the transcription factor **MITF** (Microphthalmia-associated Transcription Factor). We found that MITF is post-translationally modified by **O-GlcNAcylation**, a sugar modification that significantly enhances its stability and transcriptional activity.

Our deep dive revealed:
*   **The Mechanism**: High glucose metabolism in cancer cells drives O-GlcNAcylation of MITF.
*   **The Consequence**: Modified MITF promotes the expression of cell cycle regulators that bypass the CDK4/6 blockade.
*   **Targeting the Pathway**: Inhibiting the O-GlcNAc transferase (OGT) or downstream MITF targets re-sensitizes resistant cells to therapy.

This work links cancer metabolism (glucose usage) directly to drug resistance via a specific molecular switch, offering new targets for combination therapies.
